Randevu Hattı444 0 600
Randevu Al

Uluslararası Konferans Bilgileri

Prof. Dr. Metin Başaranoğlu'nun bildire bulunduğu tüm uluslarası konferanslara aşağıdan erişebilirsiniz.
  1. Basaranoglu M. In addition to the adenocancer events, the risk of NET increased in patients with Crohn’s.Falk meeting. Kyoto, Japan, 2018.
  2. Basaranoglu M. A patient with crohn’s disease during remission by biologics, then developed tb: determining the eating habits. Tailored therapies for IBD: A look into the future. FALK Meeting. Milan. 2018.
  3. Basaranoglu M. Prevalence of ulcerative colitis in Celiac Disease. Crossing new borders in IBD. Falk meeting. Lisbon. 2018.
  4. Basaranoglu M. Rate and predictors of endoscopic mucosal healing in patients with inflammatory Bowel disease by azathioprine treatment. IBD: Biologic Bariers. Berlin. Falk meeting. 2017.
  5. Basaranoglu M et al. As a significant cohort “nonalcoholic fatty liver disease with portal vein thrombosis” impacting liver transplantation waiting list. ESOT, BRUSSELS. 2015.
  6. Basaranoglu M et al. Diagnostic yield of colonoscopic images and biopsy results by tuberculosis culture (solid and liquid) in patients with intestinal ulceration. European Chron’s and Colitis Organization. February 2015.
  7. Basaranoglu M et al. Characteristics of 665 patients with esophageal varices. EASL monothematic conference. Innsbruck, Austria, 26-28 February, 2015.
  8. Basaranoglu M, et al. Percutaneous liver biopsy for Cholangiocarsinoma: As a single centre experience. APASL. Shangai. March 2015
  9. Basaranoglu M et al. Mıgrated fısh bone caused lıver abscess presented as a gastroıntestınal stromal tumor dıagnosed by echoendoscopy. APASL. Shangai. March 2015
  10. Basaranoglu M, et al. Increased frequency of endoscopıc mucosal healıng and reduced ıntestınal resectıon ın patıents wıth severe ıbd by longterm azathıoprıne therapy, but negatıvely affected by male gender. UEGW 18-22 October 2014, Vienna.
  11. Basaranoglu M, et al. Increased prevalence of chronic liver and pancreas abnormalities ın patıents wıth celiac dısease. UEGW 18-22 October 2014, Vienna.
  12. Basaranoglu M, Yüksel M, Ergün F, Kacar S. The prevalence of pancreas abnormalities in patients with inflammatory bowel disease was screened by US and further examined by EUS: not frequent, but also not rare! Pancreatology, Volume 14, Issue 3, S117. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
  13. Basaranoglu M, Yüksel M, Yüceer C, Yildiz H, Bilge Z. Increased prevalence of chronic type pancreas parancyhmal changes in patients with celiac disease characterized by echoendoscopy. Pancreatology, Volume 14, Issue 3 , S41. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
  14. Kacar S, Parlak E, Disibeyaz S, Basaranoglu M et al. Pancreas divisum: As a cause of chronic pancreatitis, even adenocancer? Pancreatology, Volume 14, Issue 3 , S104. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
  15. Kacar S, Basaranoglu M et al. Ulcerative colitis, Crohns disease, celiac disease and glucogen storage disease: As a cause of chronic pancreatitis in a small group of patients! Pancreatology, Volume 14 , Issue 3 , S117. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
  16. Basaranoglu M and Yüksel M. Increased prevalence of gallbladder&pancreas and lower GI tract abnormalities in patients with primary biliary cirrhosis. EASL Monothematic Conference in Primary Biliary Cirrhosis. 2014. May 23-4. Milan. Italy.
  17. Basaranoglu M, Yüksel M, et al. Evaluation of undiagnosed liver masses, not exhibit typical features but HCC, even HCC with stage C. The 3th world congress on controversies in the menagement of viral hepatitis (C- Hep), EASL 2014. May 1-3. Berlin. Germany.
  18. Kacar S, Basaranoglu M et al. Paranchymal changes of the pancreas in patients with IBD was not frequent among the patients with chronic pancreatitis. Falk Meeting. May 29-31, 2014. Paris, France.
  19. Basaranoglu M, Yüksel M, et al. The prevalence of liver, biliary tract and pancreas abnormalities in patients with inflammatory bowel disease screened by US: not frequent, but also not rare. Falk Meeting. May 29-31, 2014. Paris, France.
  20. Taskiran I, Basaranoglu M, et al. Characterization of 41 PSC patients with IBD and long-term follow-up results. Falk Meeting. May 29-31, 2014. Paris, France.
  21. Basaranoglu M, et al. Long term follow-up results of 14 IBD patients with PSC&dominant stricture. 9th Congress of ECCO – Inflammatory Bowel Diseases February 20-22, 2014 in Copenhagen, Denmark.
  22. Basaranoglu M, et al. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis may increase prevalence of primary sclerosing cholangitis with dominant stricture in a short period like 24 months. 9th Congress of ECCO – Inflammatory Bowel Diseases February 20-22, 2014 in Copenhagen, Denmark.
  23. Basaranoglu M, et al. Increased beta cell function in patients with NAFLD and PCO. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
  24. Basaranoglu M, et al. Crohn’s Disease diagnosed by double balloon enteroscopy. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
  25. Basaranoglu M, et al. Colonic strictures due to CD treated by 18 months adalimumab injection therapy. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
  26. Basaranoglu M, et al. Is there a delay on health care seeking in patients with IBD. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
  27. Basaranoglu M, Binnur Canbakan, Kemal Yildiz, Bahadır Ceylan, Birol Baysal, Hakan Sentürk. Whether the existence of fat in the liver increases the risk of cancer and operation. AASLD annual meeting. November 2012, Boston, USA.
  28. Kalem F, Basaranoglu M. The seroprevelance of HBV and HCV at the first step health organizations and urban vs rural areas. Falk Meeting. October 1-6, 2012. London, UK.
  29. Ince AT, Danalıoglu A, Yildiz K, Cinar A, Basaranoglu M, Sentürk H. Home treatment of patıents wıth acute pancreatıtıs: a prelımınary report. UEGW. October, 2012.
  30. Zülfikar Polat, Ahmet Uygun, Basaranoglu M, Fatih Aslan, Nuri Ercin, Gürkan Celebi, Mustafa Gülsen, Sait Bagcı. TWEAK in the mechanism of development of nonalcoholic fatty liver disease. Controversises in gastroenterology. Falk Meeting. October 4-6, 2012. Mainz Germany.
  31. Bahadir Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and Basaranoglu M. Long term follow-up of patients with anti-hepatitis D antibody. Controversises in gastroenterology. Falk Meeting. October 4-6, 2012. Mainz Germany.
  32. Kalem F, Özdemir M, Basaranoglu M, Toy H, Baysal B. Helicobacter pylori isolates recovered from antral gastric biopsies of patients with dyspeptic symptoms: antimicrobial resistance of metronidazole, clarithromycin and amoxicillin. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
  33. Bahadir Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and Basaranoglu M. The variables predıctıng the virological response and resistance to adefovir therapy in cases with chronic hepatitis b. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
  34. Bahadir Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and Basaranoglu M. Predictors of liver fibrosis in patients with chronic hepatitis c virus infection. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
  35. Kemal Yildiz, Mukaddes Tozlu, Ali Tüzün Ince, Orhan Kocaman, Birol Baysal, Basaranoglu M. Hakan Sentürk. A Giant Left Adrenal Pseudocyst Diagnosed by Echoendoscopy & Laparoscopic Adrenalectomy Performed. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
  36. Beyazit Y, Sayilir A, Basaranoglu M. Increased ace in extrahepatic cholangiocarcinoma as a clue for activated ras in biliary neoplasms. UEGW. 21-26 October, 2011. Sweeden.
  37. Yavuz Beyazit, Turkey; Burak Suvak; Serkan Torun; Abdurrahim Sayilir; Basaranoglu M. Mean platelet volume as an indicator of disease severity in acute pancreatitis. UEGW. 21-26 October, 2011. Sweeden.
  38. Basaranoglu M, et al. Seasonal variations in patients with IBD with new onset of disease. Falk meeting. Bruxelles 2011.
  39. Basaranoglu M, et al. Longterm follow-up in IBD patients with colonic stricture. Falk meeting. Bruxelles 2011.
  40. Basaranoglu M, et al. Our results from Turkey. Ankaferd hemostat for the management of upper gastrointestinal hemorrhages. Falk Meeting 15-16 June 2011, Hannover, Germany.
  41. Nessar G, Basaranoglu M, et al. Surgical management of obstructive Crohn’s disease in adults: Long-term results of a tertiary referal center. Falk Meeting 15-16 April 2011, Berlin, Germany.
  42. Basaranoglu M, Turhan T. Mallory Denk Bodies in chronic hepatitis and its importance. The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011)17-20 February 2011, QSNCC, Bangkok Thailand.
  43. Basaranoglu M, et al. Ankaferd hemostat for the management of upper gastrointestinal hemorrhages: a metaanalysis. Falk Meeting 15-16 April 2011, Berlin, Germany.
  44. Basaranoglu M, et al. Basic mechanism of Ankaferd Blood Stopper. Falk Meeting 15-16 April 2011, Berlin, Germany (bu çalışma ile 2. the best abstract award kazandık).
  45. Basaranoglu M et al. Does the immunosuppression induce hcv chronicity ? Long term observation of kidney recipients. ETCO, European Organ Donation Congress. 24-26 September 2010 Cardiff Wales, UK.
  46. Basaranoglu M et al. Predictive value of post-transplant amylase elevation on renal impairment; is amylase substituted to serum creatinine? ETCO, European Organ Donation Congress. 24-26 September 2010 Cardiff Wales, UK.
  47. Basaranoglu M, et al. Prevalence and Consultation Behaviour of Self-Reported Rectal Bleeding by Face-to-Face Interview in an Asian Community. IGA-AGA Institute Joint Meeting. Tel Aviv. 7, 8 February 2008.
  48. Basaranoglu M, et al. The prevalence and risk factors associated with post-infective irritable bowel syndrome (PI-IBS) developed in hospitalized patients due to acute bacterial gastroenteritis. IGA-AGA Institute Joint Meeting. Tel Aviv. 7, 8 February 2008.
  49. Neuschwander-Tetri BA, Basaranoglu M, Lisa M. Yerian, Laura H. Tetri, Elizabeth M. Brunt. Resolution of hepatic steatosis despite persistent obesity in mice fed standard rodent chow after induction of type 2 NAFLD using the American Diet Induced Obesity Syndrome model. AASLD in Boston November 2007.
  50. Tetri LH; Brunt EM; Basaranoglu M; Neuschwander-Tetri BA. Rapid onset of impaired glucose tolerance and pediatric type NAFLD in sedentary mice fed a fast-food type diet. In DDW, Washington, USA, May 2007.
  51. Basaranoglu M; Tetri, LH; Brunt EM; Neuschwander-Tetri, BA. Paradoxical Changes in Insulin Tolerance in Mice with NAFLD Induced by Sedentary Activity and an American Fast Food Type Diet. In CSCR/MWAFMR 2007 Annual Meeting, Chicago, USA, April 2007.
  52. Basaranoglu M, Özbay G, Caldwell SH, et al. Refinement of a clinicopathological typing system for NAFL. AASLD in Boston, Oct-Nov 2003.
  53. Ipekci S, Basaranoglu M, et al. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. AASLD in Atlanta. 2002.
  54. SS. Demirkok, Basaranoglu M,  et al. Seasonal variation of the onset of presentations in patients with sarcoidosis presented with BHL alone. ERS. Denmark. 2005.
  55. SS. Demirkok, Basaranoglu M,  et al. Predicting the course of sarcoidosis with clinical factors. ERS. Denmark. 2005.
  56. SS. Demirkok, Basaranoglu M,  et al. Seasonal pattern in the onset of patients with sarcoidosis in Turkey. American Torasic Society Annual Meeting. 2005.
  57. SS. Demirkok, Basaranoglu M,  et al. Erythema nodosum due to sarcoidosis vs other causes. American Torasic Society Annual Meeting. 2005.
  58. Basaranoglu M,  et al. Serum levels of triglyceride and insulin resistance in patients with nonalcoholic steatohepatitis. AASLD single topic conference in Atlanta. 2002.
  59. Özsine S, Basaranoglu M, et al. Sex and NASH. AASLD in Atlanta. 2002.
  60. Sonsuz, A; Basaranoglu M; Bilir, M; Ozdemir, S; Ozbay, G; Senturk, H; Akin, P. Relationship between histopathologic findings and aminotransferase level patients with nonalcoholic steatohepatitis. Annual AASLD Meeting in Boston November 1998.
  61. Basaranoglu M; Sonsuz, A; Bilir, M; Ozdemir, S; Acbay, O; Ozbay, G; Senturk, H; Akin, P. A controlled trial of gemfibrozil in the treatment of nonalcoholic steatohepatitis. Annual AASLD Meeting in Boston November 1998.
https://metinbasaranoglu.com.tr/wp-content/uploads/2024/03/Prof.-Dr.-Metin-Basaranoglu.png

Prof. Dr. Metin Başaranoğlu (Gastroenterolog ve Hepatolog)

Bezmialem Vakıf Ünivesitesi (BAVÜ) Gastroenteroloji Hepatoloji Bölümü Öğretim Üyesi

Menü
Faydalı Linkler
İletişim
444 0 600
metin_basaranoglu@yahoo.com
Adnan Menderes Bulvarı (Vatan Cad.) P.K. 34093 Fatih / İstanbul

©2023 Prof.Dr. Metin Başaranoğlu. All rights reserved. | Digibus tarafından yapılmıştır.